Affordable Access

Access to the full text

A prospective study on therapeutic gain by concurrent chemoradiotherapy for stage II–IV a nasopharyngeal carcinoma

Authors
  • Qi, Mei1
  • Guangyuan, Hu1
  • Guoxian, Long1
  • Hong, Qiu1
  • Qiang, Fu1
  • Guoqing, Hu1
  • 1 Huazhong University of Science and Technology, Cancer Center, Tongji Hospital, Tongji Medical College, Wuhan, 430030, China , Wuhan (China)
Type
Published Article
Journal
Journal of Huazhong University of Science and Technology [Medical Sciences]
Publisher
Huazhong University of Science and Technology
Publication Date
Feb 19, 2011
Volume
31
Issue
1
Pages
58–61
Identifiers
DOI: 10.1007/s11596-011-0150-8
Source
Springer Nature
Keywords
License
Yellow

Abstract

The benefit achieved by concurrent chemoradiotherapy (CCR) and sequential chemoradiotherapy (SCR) vs radiotherapy (RT) alone for patients with stage II–IVa nasopharyngeal carcinoma (NPC) was compared. A total of 113 patients with stage II–IV a NPC were allotted into CCR group (n=38), SCR group (n=36) and RT alone group (n=39). All patients were irradiated with the same RT technique to ≥66 Gy at 2 Gy per fraction, conventional 5 fractions/week in all groups. The CCR group received concurrent chemotherapy of weekly cisplatin for 7 weeks, and the SCR group received neoadjuvant and (or) adjuvant chemotherapy. The results showed that the 3- and 5-year overall survival rate was significantly higher in CCR group than in RT alone group (92.16% vs 61.54%, 81.58% vs 51.28%, P<0.005). The median survival time was significantly longer in CCR group than in RT alone group (67.8 months vs 52.7 months, P<0.005). It was concluded that CCR could significantly improve overall survival rate, progression-free survival rate, and median survival time when compared with RT alone.

Report this publication

Statistics

Seen <100 times